

## Disclosures

### Personal Commercial (7)

| Company Name        | Relationship Category                  | Compensation Level       | Topic Area(s)          |
|---------------------|--|--------------------------|------------------------|
| <i>Self</i>         |  |                          |                        |
| Bracco              | Speaker's Bureau                       | Modest (< \$5,000)       | Noninvasive Imaging    |
| Cytokinetics        | Data Safety Monitoring Board           | Modest (< \$5,000)       | General Cardiology     |
| Hitachi Inc         | Other - <i>instrument loan</i>         | None (\$0)               |                        |
| Jena Valve          | Consultant Fees/Honoraria              | Significant (>= \$5,000) | Valvular Heart Disease |
| Novartis            | Research/Research Grants               | None (\$0)               | Prevention             |
| ResMed Foundation   | Other - <i>Foundation Board member</i> | Modest (< \$5,000)       | General Cardiology     |
| Zoll Pharmaceutical | Speaker's Bureau                       | Significant (>= \$5,000) | General Cardiology     |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Entity Name   | Relationship Category | Compensation Level | Topic Area(s)      |
|------------------------------|-----------------------|--------------------|--------------------|
| <i>Self</i>                  |                       |                    |                    |
| none<br>† <i>Ventrix Inc</i> | Other                 | Modest (< \$5,000) | General Cardiology |

### Clinical Trial Enroller (3)

| Trial Name                             | Trial Sponsor                 | Trial Funding Source          |
|--|-------------------------------|-------------------------------|
| Akcea Evaluation of Reduction of Lp(a) | Ionis Pharma                  |                               |
| AKCEA; Trial Reducing Lp(a)            | Isis Pharmaceuticals, Inc.    |                               |
| CIRTrial                               | National Institutes of Health | National Institutes of Health |

### Institutional Financial Decision-Making Role (1)

| Funding Source             | Institutional Compensation Level |
|----------------------------|----------------------------------|
| Heartflow DMSB for PRECISE | Modest (< \$5,000)               |

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 10/15/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/15/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 10/15/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 10/15/2024

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.